Please use this identifier to cite or link to this item: https://www.arca.fiocruz.br/handle/icict/42004
Full metadata record
DC FieldValue
dc.contributor.authorFernandes, Rafaela S.
dc.contributor.authorFreire, Marjorie C. L. C.
dc.contributor.authorBueno, Renata V.
dc.contributor.authorGodoy, Andre S.
dc.contributor.authorGil, Laura H. V. G.
dc.contributor.authorOliva, Glaucius
dc.date.accessioned2020-06-30T15:42:31Z
dc.date.available2020-06-30T15:42:31Z
dc.date.issued2020
dc.identifier.citationFERNANDES, Rafaela S. et al. Reporter Replicons for Antiviral Drug Discovery against Positive Single-Stranded RNA Viruses. Viruses, v .12, n 598, p. 2-22, 2020.
dc.identifier.issn1999-4915
dc.identifier.urihttps://www.arca.fiocruz.br/handle/icict/42004
dc.language.isoeng
dc.publisherMDPI
dc.rightsopen access
dc.titleReporter Replicons for Antiviral Drug Discovery against Positive Single-Stranded RNA Viruses
dc.typeArticle
dc.identifier.doi10.3390/v12060598
dc.description.abstractenSingle-stranded positive RNA ((+) ssRNA) viruses include several important human pathogens. Some members are responsible for large outbreaks, such as Zika virus, West Nile virus, SARS-CoV, and SARS-CoV-2, while others are endemic, causing an enormous global health burden. Since vaccines or specific treatments are not available for most viral infections, the discovery of direct-acting antivirals (DAA) is an urgent need. Still, the low-throughput nature of and biosafety concerns related to traditional antiviral assays hinders the discovery of new inhibitors. With the advances of reverse genetics, reporter replicon systems have become an alternative tool for the screening of DAAs. Herein, we review decades of the use of (+) ssRNA viruses replicon systems for the discovery of antiviral agents. We summarize different strategies used to develop those systems, as well as highlight some of the most promising inhibitors identified by the method. Despite the genetic alterations introduced, reporter replicons have been shown to be reliable systems for screening and identification of viral replication inhibitors and, therefore, an important tool for the discovery of new DAAs.
dc.creator.affilliationUniversidade de São Paulo. Instituto de Física de São Carlos. São Carlos, SP, Brasil.
dc.creator.affilliationUniversidade de São Paulo. Instituto de Física de São Carlos. São Carlos, SP, Brasil.
dc.creator.affilliationUniversidade de São Paulo. Instituto de Física de São Carlos. São Carlos, SP, Brasil.
dc.creator.affilliationUniversidade de São Paulo. Instituto de Física de São Carlos. São Carlos, SP, Brasil.
dc.creator.affilliationFundação Oswaldo Cruz. Instituto Aggeu Magalhães. Recife, PE, Brasil.
dc.creator.affilliationUniversidade de São Paulo. Instituto de Física de São Carlos. São Carlos, SP, Brasil.
dc.subject.enReplicon Systems
dc.subject.en(+) ssRNA viruses
dc.subject.enDirect-acting antivirals
dc.subject.enDrug Discovery
dc.subject.enSARS-CoV-2
dc.subject.enCOVID-19
dc.subject.enCoronavirus
Appears in Collections:PE - IAM - Artigos de Periódicos

Files in This Item:
File Description SizeFormat 
Fernandes_Rafaela_etal_IAM_2020_COVID-19.pdf1.56 MBAdobe PDFView/Open



FacebookTwitterDeliciousLinkedInGoogle BookmarksBibTex Format mendeley Endnote DiggMySpace

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.